Streetbeat News

Analyst Ratings

GTHX

HC Wainwright & Co. analyst Edward White reiterates a Buy rating on G1 Therapeutics (NASDAQ:GTHX) and maintains an $11 price target.

Portfolio Pulse from richadhand@benzinga.com

June 05, 2023 | 10:28 am

COGT

Needham analyst Ami Fadia reiterates a Buy rating on Cogent Biosciences (NASDAQ:COGT) and maintains a $21 price target.

Portfolio Pulse from richadhand@benzinga.com

June 05, 2023 | 10:27 am

RAPT

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on RAPT Therapeutics (NASDAQ:RAPT) and maintained a $41 price target.

Portfolio Pulse from richadhand@benzinga.com

June 05, 2023 | 10:26 am

TNDM

Citigroup analyst Joanne Wuensch maintains a Buy rating on Tandem Diabetes Care (NASDAQ:TNDM) but lowers the price target from $55 to $45.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 10:25 am

AQST

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Aquestive Therapeutics (NASDAQ:AQST) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

June 05, 2023 | 10:24 am

JAZZ

Needham analyst Ami Fadia reiterates a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and maintains a $226 price target.

Portfolio Pulse from richadhand@benzinga.com

June 05, 2023 | 10:23 am

CNMD

Needham analyst Mike Matson maintains a Buy rating on Conmed (NYSE:CNMD) and raises the price target from $135 to $139.

Portfolio Pulse from richadhand@benzinga.com

June 05, 2023 | 10:22 am

REPL

HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Replimune Group (NASDAQ:REPL) and raises the price target from $50 to $51.

Portfolio Pulse from richadhand@benzinga.com

June 05, 2023 | 10:21 am

BARK

Citigroup analyst Ygal Arounian maintains a Buy rating on BARK (NYSE:BARK) but lowers the price target from $2.2 to $1.5.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 10:20 am

GTBP

HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on GT Biopharma (NASDAQ:GTBP) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

June 05, 2023 | 10:20 am